In this review article, Kelly compiled the roles of several approaches of immunotherapy and their successful treatments of esophageal and gastric cancers in which PD-L2 expression has been reported in 52% of esophageal adenocarcinomas. This evidence concerns the gene PDCD1LG2 and esophageal adenocarcinoma.